GLP-1 pills are coming, and they could revolutionize weight-loss
Sep 17, 2024 · Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience.
Beyond Ozempic: New GLP-1 drugs promise weight loss and …
Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. Some of the experimental drugs may...
Ozempic lures people to the doctor, Nestle's GLP-1 'shot,' an
2 days ago · The news could put pressure on companies that have been able to sell off-brand versions of GLP-1 weight-loss drugs because of widespread shortages. Read More CVS filled a ‘massive’ amount of ...
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts …
3 days ago · The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end. ... The company's stock slid more than 13% on the news, trading at less than $0.30 per share.
GLP-1 compounding is still in limbo. Will the FDA leave it for the …
Dec 11, 2024 · About 12% of American adults have taken a GLP-1 medication, according to a May poll from KFF Health. And compounded versions may account for upwards of 20% of all GLP-1 prescriptions, CNN reported. But when the FDA backed down, letting compound pharmacies resume, the industry was still awaiting final word. That decision could take a while.
Many people using GLP-1s for weight loss stop treatment too soon ... - CNN
May 21, 2024 · An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications – about 58% – were on their treatment plan for less than 12 weeks, falling short of a key...
GLP-1 nonresponders: Up to 1 in 5 people don't lose weight | AP News
Nov 23, 2024 · In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of …
FDA clarifies policies for compounders as national GLP-1 supply …
Oct 22, 2024 · The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
As many as 1 in 5 people won't lose weight with GLP-1 drugs ... - CBS News
Nov 25, 2024 · About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to several obesity experts.
Pairing up with GLP-1 to combat obesity - Nature
5 days ago · Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. ... An essential round-up of science news, opinion and analysis, delivered to ...